These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32696281)

  • 1. Performance of the 2017 EUSTAR activity index in an scleroderma cohort.
    Ross L; Stevens W; Wilson M; Huq M; Strickland G; Walker J; Sahhar J; Ngian GS; Roddy J; Youssef P; Proudman S; Nikpour M
    Clin Rheumatol; 2020 Dec; 39(12):3701-3705. PubMed ID: 32696281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
    Nevskaya T; Baron M; Pope JE;
    Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NEMO score in nailfold videocapillaroscopy is a good tool to assess both steady state levels and overtime changes of disease activity in patients with systemic sclerosis: a comparison with the proposed composite indices for this disease status entity.
    Pignataro F; Maglione W; Minniti A; Sambataro D; Sambataro G; Campanaro F; Valentini G; Vitali C; Del Papa N
    Arthritis Res Ther; 2019 Nov; 21(1):258. PubMed ID: 31783890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.
    Fasano S; Riccardi A; Messiniti V; Caramaschi P; Rosato E; Maurer B; Smith V; Siegert E; De Langhe E; Riccieri V; Airó P; Mihai C; Avouac J; Zanatta E; Walker UA; Iannone F; García De la Peña Lefebvre P; Distler JHW; Vacca A; Distler O; Kowal-Bielecka O; Allanore Y; Valentini G
    Ann Rheum Dis; 2019 Dec; 78(12):1681-1685. PubMed ID: 31422354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.
    Valentini G; Iudici M; Walker UA; Jaeger VK; Baron M; Carreira P; Czirják L; Denton CP; Distler O; Hachulla E; Herrick AL; Kowal-Bielecka O; Pope J; Müller-Ladner U; Riemekasten G; Avouac J; Frerix M; Jordan S; Minier T; Siegert E; Ong VH; Vettori S; Allanore Y
    Ann Rheum Dis; 2017 Jan; 76(1):270-276. PubMed ID: 27621285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less severe disease in patients with early systemic sclerosis?
    Horimoto AMC; Camargo CZ; Kayser C
    Mod Rheumatol; 2019 Nov; 29(6):977-983. PubMed ID: 30472907
    [No Abstract]   [Full Text] [Related]  

  • 8. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria.
    Valentini G; Bencivelli W; Bombardieri S; D'Angelo S; Della Rossa A; Silman AJ; Black CM; Czirjak L; Nielsen H; Vlachoyiannopoulos PG
    Ann Rheum Dis; 2003 Sep; 62(9):901-3. PubMed ID: 12922968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis.
    Yayla ME; İlgen U; Okatan İE; UsluYurteri E; Torgutalp M; Keleşoğlu Dinçer AB; Aydemir Gülöksüz EG; Sezer S; Turgay TM; Kınıklı G; Ateş A
    Clin Rheumatol; 2020 Jan; 39(1):77-83. PubMed ID: 31317426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of disease activity indices using the 28 joint counts in systemic sclerosis.
    Lóránd V; Bálint Z; Komjáti D; Németh B; Minier T; Kumánovics G; Farkas N; Czirják L; Varjú C;
    Rheumatology (Oxford); 2016 Oct; 55(10):1849-58. PubMed ID: 27402873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease activity indices in systemic sclerosis: a systematic literature review.
    Melsens K; De Keyser F; Decuman S; Piette Y; Vandecasteele E; Smith V
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):186-192. PubMed ID: 27385265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
    Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
    Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease.
    Michalska-Jakubus M; Kowal-Bielecka O; Chodorowska G; Bielecki M; Krasowska D
    Rheumatology (Oxford); 2011 Apr; 50(4):746-55. PubMed ID: 21149250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Patient and Physician Assessments of Gastrointestinal Disease Activity in Systemic Sclerosis.
    Ross L; Proudman S; Walker J; Stevens W; Ferdowsi N; Quinlivan A; Morrisroe K; Baron M; Nikpour M
    J Rheumatol; 2023 Apr; 50(4):519-525. PubMed ID: 36379565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
    Melsens K; De Keyser F; Decuman S; Brusselle G; De Pauw M; Deschepper E; De Wilde K; Elewaut D; Piette Y; Vandecasteele E; Smith V
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):148-151. PubMed ID: 27463733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern".
    Smith V; Vanhaecke A; Herrick AL; Distler O; Guerra MG; Denton CP; Deschepper E; Foeldvari I; Gutierrez M; Hachulla E; Ingegnoli F; Kubo S; Müller-Ladner U; Riccieri V; Sulli A; van Laar JM; Vonk MC; Walker UA; Cutolo M;
    Autoimmun Rev; 2019 Nov; 18(11):102394. PubMed ID: 31520797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database.
    Gigante A; Hoffmann-Vold AM; Alunni Fegatelli D; Gabrielli A; Leodori G; Coleiro B; De Santis M; Dagna L; Alegre-Sancho JJ; Montecucco C; Carreira PE; Balbir-Gurman A; Doria A; Riemekasten G; Airò P; Distler J; Distler O; Rosato E;
    Rheumatology (Oxford); 2021 Dec; 61(1):213-222. PubMed ID: 33769468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients.
    Benvenuti F; Zanatta E; Avouac J; Müller-Ladner U; Cozzi F; Hoffmann-Vold AM; Gabrielli A; Distler O; Matucci-Cerinic M; Allanore Y; Doria A
    Expert Rev Clin Immunol; 2020 Nov; 16(11):1065-1074. PubMed ID: 33076716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.